GoAI
Get started
Achieve Life Sciences, Inc. logo

Achieve Life Sciences, Inc.

ACHV

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$7.765

−$0.225 · -2.82%

Aug 24, 10:10 AM ET

ACHV company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

27

Expensive

Momentum

68

Gaining

Sentiment

58

Mixed

Risk resilience

42

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Andrew D. Goldberg
Listed since
Oct 12, 1995
Employees
28

Market position

Day range

Current $7.765

52-week range

Current $7.765

Open
$7.98
Previous close
$7.99
Volume
193.51K
0.1× average
Average volume
1.85M
Average daily volume
Market cap
797.15M USD
Beta
2.23
Market reference 1
50-day average
$6.3502
+22.28% above average
200-day average
$4.9663
+56.35% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
210.69M USD
P/E (TTM)
-5.01×
P/B (TTM)
-49.48×
P/S (TTM)
0×
EV / EBITDA
-3.93×
Earnings yield
-25.22%
Free cash flow yield
-22.83%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-253.96%
Return on assets
-130.77%
Return on invested capital
-150.47%

Financial health

Debt / equity
-1.02×
Current ratio
4.39×

Financial statements

Income trends

Operating income

−54.88M USD-40.47%

Net income

−54.65M USD-37.21%
Income trends across reported periods−24.49M USD−35.54M USD−46.59M USD−57.64M USDOperating income, FY2021: −33.09M USDOperating income, FY2022: −40.8M USDOperating income, FY2023: −27.25M USDOperating income, FY2024: −39.07M USDOperating income, FY2025: −54.88M USDNet income, FY2021: −33.15M USDNet income, FY2022: −42.35M USDNet income, FY2023: −29.82M USDNet income, FY2024: −39.83M USDNet income, FY2025: −54.65M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −33.09M USD. Operating income FY2022 −40.8M USD. Operating income FY2023 −27.25M USD. Operating income FY2024 −39.07M USD. Operating income FY2025 −54.88M USD. Net income FY2021 −33.15M USD. Net income FY2022 −42.35M USD. Net income FY2023 −29.82M USD. Net income FY2024 −39.83M USD. Net income FY2025 −54.65M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold228K USD229K USD———
Gross profit−228K USD−229K USD———
Research and development22.96M USD22.82M USD15.81M USD30.08M USD23.97M USD
Selling, general, and administrative31.87M USD16.25M USD11.44M USD10.72M USD9.13M USD
Operating expenses54.65M USD38.84M USD27.25M USD40.8M USD33.09M USD
Interest income1.5M USD2.36M USD825K USD199K USD17K USD
Interest expense819K USD2.18M USD2.85M USD1.79M USD—
Depreciation and amortization228K USD229K USD228K USD236K USD250K USD
Operating income−54.88M USD−39.07M USD−27.25M USD−40.8M USD−33.09M USD
Net income−54.65M USD−39.83M USD−29.82M USD−42.35M USD−33.15M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-1.25
FY2025
Latest fiscal-year revenue
0 USD
FY2025
Next fiscal-year EPS consensus
-1.46
FY2026 · 7 analysts
Next fiscal-year revenue consensus
4.5M USD
FY2026 · 6 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend1.36-0.61-2.58-4.54FY21FY22FY23FY24FY25FY26FY27FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend319.98M203.63M87.27M-29.09MFY21FY22FY23FY24FY25FY26FY27FY28

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$14.00

80.30% upside
Past 12 months12-month forecastHigh $18.00Average $14.00Low $12.00

Recent analyst actions

3 institutions
Lake StreetmaintainBuy

ACHV news

globenewswire.com

Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened organization with new…

Read source
globenewswire.com

Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality

SEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global…

Read source
globenewswire.com

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization…

Read source
defenseworld.net

Achieve Life Sciences (NASDAQ:ACHV) Shares Up 6.5% – Here’s Why

Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) was up 6.5% during mid-day trading on Friday. The stock traded as high as $6.33 and last traded at $6.35. 209,257 shares were traded during trading, a decline…

Read source
marketbeat.com

Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting

Achieve Life Sciences NASDAQ: ACHV held its 2026 Annual Meeting of Stockholders virtually, with Chief Executive Officer Andrew Goldberg serving as chairperson of the meeting. Goldberg called the meeting to order and said…

Read source
seekingalpha.com

Achieve Life Sciences: Despite CRL, A Success Is Achieve-Able

The last months were eventful for Achieve Life Sciences, sending the stock strongly down, but later to a new high for the year, implying optimism about the future path. Achieve is, in my view, a more derisked case now,…

Read source

ACHV peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ACHV

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
19.96M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$376.8-0.38%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
15.59M
Weight
0.02%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.38-0.53%
Simplify Propel Opportunities ETF logoSimplify Propel Opportunities ETFSURI
Market value
11.44M
Weight
13.45%
AUM
85.05M USD
Expense ratio
2.82%
Price / 1D
$19.70-0.60%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
11.36M
Weight
0.10%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$162.34-2.05%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
6.16M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.6-0.79%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
5.83M
Weight
0.04%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$382.93-1.15%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
2.8M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.62-0.52%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
2.37M
Weight
0.04%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.665-0.57%

Continue in GoAI

Research ACHV

research.disclaimer